Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JPH203 |
| Synonyms | |
| Therapy Description |
JPH203 (KYT-0353) inhibits LAT1, potentially resulting in decreased tumor cell growth (PMID: 24492461, PMID: 19900191, PMID: 32653341). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JPH203 | KYT-0353|nanvuranlat | JPH203 (KYT-0353) inhibits LAT1, potentially resulting in decreased tumor cell growth (PMID: 24492461, PMID: 19900191, PMID: 32653341). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07265674 | Phase III | Fluorouracil + Irinotecan + Leucovorin JPH203 Fluorouracil + Leucovorin + Oxaliplatin | A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer (Beacon-BTC) | Not yet recruiting | USA | 0 |